Ethos Cannabis has officially launched a clinical research partnership with the Sidney Kimmel Medical College at Thomas Jefferson University in Pennsylvania.
This development makes Ethos the first operational company to receive this license, as well as the holder of one of only eight statewide Clinical Registrant (CR) licenses.
These licenses are issued to operators that are partnered with one of Pennsylvania’s major university health institutions. The research at Jefferson is fully funded by Ethos, a multi-state cannabis company based in Philadelphia. The goal is to determine which types of cannabis are the most effective for specific ailments, and which dosages provide effective treatment.
Ethos Cannabis’ CEO Teddy Scott told Benzinga he felt honored to announce the partnership with Thomas Jefferson University.
“Receiving this CR license is the end result of years of work behind the scenes by both parties. And the research that we will now be able to accomplish as a result will be a game-changer in regards to elevating our city as a center for serious cannabis research,” he said. “We already have several hundred patients that have pre-enrolled at our Philadelphia dispensary to get this program started.”
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
